I-Mab Signs Agreement to Divest its Assets and Business Operations in China [Yahoo! Finance]
I-MAB - American Depositary Shares (IMAB)
Company Research
Source: Yahoo! Finance
Agreement provides for a strategic focus in advancing I-Mab's potential of differentiated oncology clinical assets and builds shareholder value by streamlining the operating model, reducing operational costs, and mitigating potential associated risks The Company retains cash in hand, ex- China rights of all clinical stage assets led by givastomig (CLDN18.2/4-1BB), uliledlimab (CD73), and TJ-L14B (PD-L1/4-1BB), and remain listed on NASDAQ ROCKVILLE, Md. Feb. 7, 2024 /PRNewswire/ -- I-Mab (the " Company ") (NASDAQ: IMAB), a global biotech company exclusively focused on bringing highly differentiated immunotherapies and biologics for cancer treatment to patients around the world, today announced that as part of its strategy to become a U.S.-based biotech, its Chinese subsidiaries have entered into definitive agreements with I-Mab Biopharma ( Hangzhou ) Co., Ltd. (the " Hangzhou Company "), an unconsolidated affiliate of the Company, and a group of China -based investors to divest th
Show less
Read more
Impact Snapshot
Event Time:
IMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMAB alerts
High impacting I-MAB - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMAB
News
- I-MAB Filed 2023 Annual Report on Form 20-F [Yahoo! Finance]Yahoo! Finance
- I-MAB Filed 2023 Annual Report on Form 20-FPR Newswire
- I-Mab (NASDAQ: IMAB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.MarketBeat
- I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare ConferencePR Newswire
IMAB
Sec Filings
- 4/30/24 - Form 20-F
- 4/15/24 - Form 6-K
- 4/2/24 - Form 6-K
- IMAB's page on the SEC website